2N7B
 
 | | Solution structure of the human Siglec-8 lectin domain in complex with 6'sulfo sialyl Lewisx | | Descriptor: | 3-aminopropan-1-ol, N-acetyl-alpha-neuraminic acid-(2-3)-6-O-sulfo-beta-D-galactopyranose-(1-4)-[alpha-L-fucopyranose-(1-3)]2-acetamido-2-deoxy-beta-D-glucopyranose, Sialic acid-binding Ig-like lectin 8 | | Authors: | Proepster, J.M, Yang, F, Rabbani, S, Ernst, B, Allain, F.H.-T, Schubert, M. | | Deposit date: | 2015-09-07 | | Release date: | 2016-07-06 | | Last modified: | 2024-11-20 | | Method: | SOLUTION NMR | | Cite: | Structural basis for sulfation-dependent self-glycan recognition by the human immune-inhibitory receptor Siglec-8.
Proc.Natl.Acad.Sci.USA, 113, 2016
|
|
2N4I
 | | The solution structure of Skint-1, a critical determinant of dendritic epidermal gamma-delta T cell selection | | Descriptor: | Selection and upkeep of intraepithelial T-cells protein 1 | | Authors: | Salim, M, Knowles, T.J, Hart, R, Mohammed, F, Woodward, M.J, Willcox, C.R, Overduin, M, Hayday, A.C, Willcox, B.E. | | Deposit date: | 2015-06-18 | | Release date: | 2016-03-02 | | Last modified: | 2024-10-09 | | Method: | SOLUTION NMR | | Cite: | Characterization of a Putative Receptor Binding Surface on Skint-1, a Critical Determinant of Dendritic Epidermal T Cell Selection.
J.Biol.Chem., 291, 2016
|
|
2NMS
 | |
2LVE
 | | RECOMBINANT LEN | | Descriptor: | RLEN | | Authors: | Schiffer, M, Pokkuluri, P.R. | | Deposit date: | 1998-05-13 | | Release date: | 1999-05-18 | | Last modified: | 2024-10-09 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | A domain flip as a result of a single amino-acid substitution.
Structure, 6, 1998
|
|
2N7A
 | | Solution structure of the human Siglec-8 lectin domain | | Descriptor: | Sialic acid-binding Ig-like lectin 8 | | Authors: | Proepster, J.M, Yang, F, Rabbani, S, Ernst, B, Allain, F.H.-T, Schubert, M. | | Deposit date: | 2015-09-07 | | Release date: | 2016-07-06 | | Last modified: | 2024-11-20 | | Method: | SOLUTION NMR | | Cite: | Structural basis for sulfation-dependent self-glycan recognition by the human immune-inhibitory receptor Siglec-8.
Proc.Natl.Acad.Sci.USA, 113, 2016
|
|
7CU5
 | | N-Glycosylation of PD-1 and glycosylation dependent binding of PD-1 specific monoclonal antibody camrelizumab | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, Programmed cell death protein 1, ... | | Authors: | Liu, K.F, Tan, S.G, Jin, W.J, Guan, J.W, Wang, W.L, Sun, H, Qi, J.X, Yan, J.H, Chai, Y, Wang, Z.F, Chu, X.D, Gao, G.F. | | Deposit date: | 2020-08-21 | | Release date: | 2020-10-14 | | Last modified: | 2024-10-30 | | Method: | X-RAY DIFFRACTION (2.81 Å) | | Cite: | N-glycosylation of PD-1 promotes binding of camrelizumab.
Embo Rep., 21, 2020
|
|
7CZD
 | | Crystal structure of PD-L1 in complex with a VHH | | Descriptor: | 1,2-ETHANEDIOL, DI(HYDROXYETHYL)ETHER, Programmed cell death 1 ligand 1, ... | | Authors: | Wang, C. | | Deposit date: | 2020-09-08 | | Release date: | 2021-07-14 | | Last modified: | 2024-11-13 | | Method: | X-RAY DIFFRACTION (1.64 Å) | | Cite: | Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer.
J Immunother Cancer, 9, 2021
|
|
7BEA
 | | Structure of human Programmed cell death 1 ligand 1 (PD-L1) with inhibitor | | Descriptor: | 2-(aminomethyl)-6-[(2-methyl-3-phenyl-phenyl)methoxy]-~{N}-(2-phenylethyl)imidazo[1,2-a]pyridin-3-amine, Programmed cell death 1 ligand 1 | | Authors: | Magiera-Mularz, K, Butera, R, Wazynska, M, Holak, T, Domling, A. | | Deposit date: | 2020-12-22 | | Release date: | 2021-06-09 | | Last modified: | 2024-11-13 | | Method: | X-RAY DIFFRACTION (2.45 Å) | | Cite: | Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists.
Acs Med.Chem.Lett., 12, 2021
|
|
4ZQK
 | | Structure of the complex of human programmed death-1 (PD-1) and its ligand PD-L1. | | Descriptor: | Programmed cell death 1 ligand 1, Programmed cell death protein 1, SODIUM ION | | Authors: | Zak, K.M, Dubin, G, Holak, T.A. | | Deposit date: | 2015-05-10 | | Release date: | 2015-11-04 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (2.45 Å) | | Cite: | Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.
Structure, 23, 2015
|
|
5A2I
 | | Crystal structure of scFv-SM3 in complex with APD-SGalNAc-RP | | Descriptor: | 1,2-ETHANEDIOL, 2-acetamido-2-deoxy-alpha-D-galactopyranose, ANTIGEN TN, ... | | Authors: | Martinez-Saez, N, Castro-Lopez, J, Valero-Gonzalez, J, Madariaga, D, Companon, I, Somovilla, V.J, Salvado, M, Asensio, J.L, Jimenez-Barbero, J, Avenoza, A, Busto, J.H, Bernardes, G.J.L, Peregrina, J.M, Hurtado-Guerrero, R, Corzana, F. | | Deposit date: | 2015-05-20 | | Release date: | 2015-06-03 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (1.88 Å) | | Cite: | Deciphering the Non-Equivalence of Serine and Threonine O-Glycosylation Points: Implications for Molecular Recognition of the Tn Antigen by an Anti-Muc1 Antibody.
Angew.Chem.Int.Ed.Engl., 54, 2015
|
|
5A2J
 | | Crystal structure of scFv-SM3 in complex with the naked peptide APDTRP | | Descriptor: | 1,2-ETHANEDIOL, SCFV-SM3, THE NAKED PEPTIDE APDTRP | | Authors: | Martinez-Saez, N, Castro-Lopez, J, Valero-Gonzalez, J, Madariaga, D, Companon, I, Somovilla, V.J, Salvado, M, Asensio, J.L, Jimenez-Barbero, J, Avenoza, A, Busto, J.H, Bernardes, G.J.L, Peregrina, J.M, Hurtado-Guerrero, R, Corzana, F. | | Deposit date: | 2015-05-20 | | Release date: | 2015-06-03 | | Last modified: | 2024-11-20 | | Method: | X-RAY DIFFRACTION (1.65 Å) | | Cite: | Deciphering the Non-Equivalence of Serine and Threonine O-Glycosylation Points: Implications for Molecular Recognition of the Tn Antigen by an Anti-Muc1 Antibody.
Angew.Chem.Int.Ed.Engl., 54, 2015
|
|
5B8C
 | | High resolution structure of the human PD-1 in complex with pembrolizumab Fv | | Descriptor: | Pembrolizumab heavy chain variable region (PemVH), Pembrolizumab light chain variable region (PemVL), Programmed cell death protein 1 | | Authors: | Horita, S, Shimamura, T, Iwata, S, Nomura, N. | | Deposit date: | 2016-06-14 | | Release date: | 2016-10-26 | | Last modified: | 2024-11-20 | | Method: | X-RAY DIFFRACTION (2.146 Å) | | Cite: | High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1
Sci Rep, 6, 2016
|
|
7ELX
 | | The crystal structure of CTLA-4 and Fab | | Descriptor: | Cytotoxic T-lymphocyte protein 4, heavy chain of Fab, light chain of Fab | | Authors: | Yu, X.J, Wang, L, Yu, C.F. | | Deposit date: | 2021-04-12 | | Release date: | 2021-06-30 | | Last modified: | 2024-11-20 | | Method: | X-RAY DIFFRACTION (2.14 Å) | | Cite: | The crystal structure of CTLA-4 and Fab
To Be Published
|
|
5C9K
 | |
5A2L
 | | Crystal structure of scFv-SM3 in complex with APD-CGalNAc-RP | | Descriptor: | 1,2-ETHANEDIOL, 2-acetamido-2-deoxy-alpha-D-galactopyranose, MODIFIED ANTIGEN TN, ... | | Authors: | Martinez-Saez, N, Castro-Lopez, J, Valero-Gonzalez, J, Madariaga, D, Companon, I, Somovilla, V.J, Salvado, M, Asensio, J.L, Jimenez-Barbero, J, Avenoza, A, Busto, J.H, Bernardes, G.J.L, Peregrina, J.M, Hurtado-Guerrero, R, Corzana, F. | | Deposit date: | 2015-05-20 | | Release date: | 2015-06-03 | | Last modified: | 2024-11-06 | | Method: | X-RAY DIFFRACTION (1.79 Å) | | Cite: | Deciphering the Non-Equivalence of Serine and Threonine O-Glycosylation Points: Implications for Molecular Recognition of the Tn Antigen by an Anti-Muc1 Antibody.
Angew.Chem.Int.Ed.Engl., 54, 2015
|
|
5ACM
 | | Mcg immunoglobulin variable domain with methylene blue | | Descriptor: | 3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-IUM, GLYCEROL, MCG, ... | | Authors: | Brumshtein, B, Esswein, S.R, Salwinski, L, Phillips, M.L, Ly, A.T, Cascio, D, Sawaya, M.R, Eisenberg, D.S. | | Deposit date: | 2015-08-17 | | Release date: | 2015-12-02 | | Last modified: | 2024-11-20 | | Method: | X-RAY DIFFRACTION (1.05 Å) | | Cite: | Inhibition by small-molecule ligands of formation of amyloid fibrils of an immunoglobulin light chain variable domain.
Elife, 4, 2015
|
|
5A2K
 | | Crystal structure of scFv-SM3 in complex with APD-TGalNAc-RP | | Descriptor: | 1,2-ETHANEDIOL, 2-acetamido-2-deoxy-alpha-D-galactopyranose, ANTIGEN TN, ... | | Authors: | Martinez-Saez, N, Castro-Lopez, J, Valero-Gonzalez, J, Madariaga, D, Companon, I, Somovilla, V.J, Salvado, M, Asensio, J.L, Jimenez-Barbero, J, Avenoza, A, Busto, J.H, Bernardes, G.J.L, Peregrina, J.M, Hurtado-Guerrero, R, Corzana, F. | | Deposit date: | 2015-05-20 | | Release date: | 2015-06-03 | | Last modified: | 2024-11-13 | | Method: | X-RAY DIFFRACTION (1.7 Å) | | Cite: | Deciphering the Non-Equivalence of Serine and Threonine O-Glycosylation Points: Implications for Molecular Recognition of the Tn Antigen by an Anti-Muc1 Antibody.
Angew.Chem.Int.Ed.Engl., 54, 2015
|
|
7CGW
 | | Complex structure of PD-1 and tislelizumab Fab | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Heavy chain of tislelizumab Fab, Light chain of tislelizumab Fab, ... | | Authors: | Hong, Y, Feng, Y.C, Liu, Y. | | Deposit date: | 2020-07-02 | | Release date: | 2021-04-07 | | Last modified: | 2024-11-13 | | Method: | X-RAY DIFFRACTION (3.2 Å) | | Cite: | Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage.
Febs Open Bio, 11, 2021
|
|
7C88
 | | Complex structure of JS003 and PD-L1 | | Descriptor: | JS003 Heavy chain, JS003 Light chain, Programmed cell death 1 ligand 1 | | Authors: | Bi, X, Shi, R, Chai, Y, Qi, J, Yan, J, Tan, S. | | Deposit date: | 2020-05-29 | | Release date: | 2021-04-14 | | Last modified: | 2024-10-09 | | Method: | X-RAY DIFFRACTION (1.997 Å) | | Cite: | Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy.
Signal Transduct Target Ther, 5, 2020
|
|
7BXA
 | | Crystal structure of PD-1 in complex with tislelizumab Fab | | Descriptor: | Programmed cell death protein 1, heavy chain, light chain | | Authors: | Heo, Y.S, Lee, S.H, Lim, H, Lee, H.T, Kim, Y.J, Park, E.B. | | Deposit date: | 2020-04-18 | | Release date: | 2020-06-10 | | Last modified: | 2024-11-13 | | Method: | X-RAY DIFFRACTION (3.32 Å) | | Cite: | Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy.
Biochem.Biophys.Res.Commun., 527, 2020
|
|
5ACL
 | | Mcg immunoglobulin variable domain with sulfasalazine | | Descriptor: | 2-HYDROXY-(5-([4-(2-PYRIDINYLAMINO)SULFONYL]PHENYL)AZO)BENZOIC ACID, MCG, SULFATE ION | | Authors: | Brumshtein, B, Esswein, S.R, Salwinski, L, Phillips, M.L, Ly, A.T, Cascio, D, Sawaya, M.R, Eisenberg, D.S. | | Deposit date: | 2015-08-17 | | Release date: | 2015-12-02 | | Last modified: | 2024-11-13 | | Method: | X-RAY DIFFRACTION (1.49 Å) | | Cite: | Inhibition by small-molecule ligands of formation of amyloid fibrils of an immunoglobulin light chain variable domain.
Elife, 4, 2015
|
|
7DV4
 | | Crystal structure of anti-CTLA-4 VH domain in complex with human CTLA-4 | | Descriptor: | 1,2-ETHANEDIOL, 4003-1(VH), Cytotoxic T-lymphocyte protein 4 | | Authors: | Li, H, Gan, X, He, Y. | | Deposit date: | 2021-01-12 | | Release date: | 2022-01-12 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (2.38 Å) | | Cite: | An anti-CTLA-4 heavy chain-only antibody with enhanced T reg depletion shows excellent preclinical efficacy and safety profile.
Proc.Natl.Acad.Sci.USA, 119, 2022
|
|
5AYQ
 | |
5C2B
 | | anti-CXCL13 parental scFv - 3B4 | | Descriptor: | CHLORIDE ION, scFv 3B4 | | Authors: | Tu, C, Bard, J, Mosyak, L. | | Deposit date: | 2015-06-15 | | Release date: | 2015-11-04 | | Last modified: | 2024-10-30 | | Method: | X-RAY DIFFRACTION (1.4049 Å) | | Cite: | Optimization of a scFv-based biotherapeutic by CDR side-chain clash repair
To Be Published
|
|
5C6W
 | | anti-CXCL13 scFv - E10 | | Descriptor: | 1,2-ETHANEDIOL, CHLORIDE ION, DI(HYDROXYETHYL)ETHER, ... | | Authors: | Tu, C, Bard, J, Mosyak, L. | | Deposit date: | 2015-06-23 | | Release date: | 2015-11-04 | | Last modified: | 2024-10-30 | | Method: | X-RAY DIFFRACTION (1.54 Å) | | Cite: | Optimization of a scFv-based biotherapeutic by CDR side-chain clash repair
To Be Published
|
|
